179 related articles for article (PubMed ID: 31771990)
1. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.
Tateishi K; Ko R; Shukuya T; Okuma Y; Watanabe S; Kuyama S; Murase K; Tsukita Y; Ashinuma H; Nakagawa T; Uematsu K; Nakao M; Mori Y; Kaira K; Mouri A; Miyabayashi T; Sakashita H; Matsumoto Y; Tanigawa T; Koizumi T; Morita S; Kobayashi K; Nukiwa T; Takahashi K;
Oncologist; 2020 Apr; 25(4):e668-e674. PubMed ID: 31771990
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.
Ko R; Shukuya T; Okuma Y; Tateishi K; Imai H; Iwasawa S; Miyauchi E; Fujiwara A; Sugiyama T; Azuma K; Muraki K; Yamasaki M; Tanaka H; Takashima Y; Soda S; Ishimoto O; Koyama N; Morita S; Kobayashi K; Nukiwa T; Takahashi K;
Oncologist; 2018 Oct; 23(10):1210-1217. PubMed ID: 29567820
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.
Wang Y; Zhang X; Tian D; Han S; Zhang J; Nie J; Dai L; Hu W; Chen X; Ma X; Tian G; Wu D; Zhang Z; Long J; Fang J
Cancer Med; 2023 Feb; 12(3):2303-2311. PubMed ID: 35924403
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
Ma WL; Lin CC; Hsu FM; Lee JM; Chen JS; Huang YL; Chang YL; Chang CH; Yang JC
Cancer Med; 2022 Sep; 11(18):3445-3456. PubMed ID: 35348307
[TBL] [Abstract][Full Text] [Related]
5. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.
Agatsuma T; Koizumi T; Kanda S; Ito M; Urushihata K; Yamamoto H; Hanaoka M; Kubo K
J Thorac Oncol; 2011 Dec; 6(12):2130-4. PubMed ID: 21892103
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
Ho IW; Pan YL; Lai JI; Liu CY
Thorac Cancer; 2024 Feb; 15(4):339-346. PubMed ID: 38149471
[TBL] [Abstract][Full Text] [Related]
9. Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma.
Okuma Y; Hosomi Y; Takahashi S; Maeda Y; Okamura T; Hishima T
Clin Lung Cancer; 2015 May; 16(3):221-7. PubMed ID: 25468802
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel for platinum-refractory advanced thymic carcinoma.
Watanabe N; Umemura S; Niho S; Kirita K; Matsumoto S; Yoh K; Ohmatsu H; Goto K
Jpn J Clin Oncol; 2015 Jul; 45(7):665-9. PubMed ID: 25840444
[TBL] [Abstract][Full Text] [Related]
11. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature.
Watanabe K; Shinkai M; Goto H; Yoshikawa S; Yamaguchi N; Hara Y; Shinoda M; Moriyama Y; Rubin BK; Ishigatsubo Y; Kaneko T
Tumori; 2013; 99(4):e172-6. PubMed ID: 24326856
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.
Okuma Y; Hosomi Y; Takagi Y; Iguchi M; Okamura T; Shibuya M
Lung Cancer; 2011 Dec; 74(3):492-6. PubMed ID: 21665316
[TBL] [Abstract][Full Text] [Related]
14. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy.
Okuma Y; Saito M; Hosomi Y; Sakuyama T; Okamura T
J Cancer Res Clin Oncol; 2015 Feb; 141(2):323-31. PubMed ID: 25146529
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and prognosis in advanced thymic carcinoma patients.
Song Z; Yu X; Zhang Y
Clinics (Sao Paulo); 2015 Dec; 70(12):775-80. PubMed ID: 26735216
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy for thymic carcinoma].
Okuma Y
Gan To Kagaku Ryoho; 2012 May; 39(5):702-7. PubMed ID: 22584319
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases.
Kanda S; Koizumi T; Komatsu Y; Yoshikawa S; Okada M; Hatayama O; Yasuo M; Tsushima K; Urushihata K; Kubo K; Sasabayashi M; Takamizawa A
Anticancer Res; 2007; 27(4C):3005-8. PubMed ID: 17695487
[TBL] [Abstract][Full Text] [Related]
18. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
Sato J; Satouchi M; Itoh S; Okuma Y; Niho S; Mizugaki H; Murakami H; Fujisaka Y; Kozuki T; Nakamura K; Nagasaka Y; Kawasaki M; Yamada T; Machida R; Kuchiba A; Ohe Y; Yamamoto N
Lancet Oncol; 2020 Jun; 21(6):843-850. PubMed ID: 32502444
[TBL] [Abstract][Full Text] [Related]
20. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Hirai F; Seto T; Inamasu E; Toyokawa G; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Anticancer Res; 2014 Oct; 34(10):5743-7. PubMed ID: 25275083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
